JPH07509006A - 3-[N-(2-Mercaptopropionyl-aminoacetyl)]-tetrahydrothiazolyl-4-carboxylic acid as an anti-inflammatory and immunostimulant - Google Patents
3-[N-(2-Mercaptopropionyl-aminoacetyl)]-tetrahydrothiazolyl-4-carboxylic acid as an anti-inflammatory and immunostimulantInfo
- Publication number
- JPH07509006A JPH07509006A JP6524965A JP52496594A JPH07509006A JP H07509006 A JPH07509006 A JP H07509006A JP 6524965 A JP6524965 A JP 6524965A JP 52496594 A JP52496594 A JP 52496594A JP H07509006 A JPH07509006 A JP H07509006A
- Authority
- JP
- Japan
- Prior art keywords
- inflammatory
- carboxylic acid
- mercapto
- acetyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
(57)【要約】本公報は電子出願前の出願データであるため要約のデータは記録されません。 (57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】 抗炎症および免疫刺激剤としての3− [N−(2−メルカプト−プロピオニル −アミノ−アセチル)]−]テトラヒドローチアゾリルー4−カルボン 酸発明は、3− [N−(2−メルカプト−プロピオニル−アミノ−アセチル) ]−]テトラヒドローチアゾリルー4−カルボンの新規な治療用途を目的とする 。[Detailed description of the invention] 3-[N-(2-mercapto-propionyl) as an anti-inflammatory and immunostimulant -amino-acetyl)]-]tetrahydrothiazolyl-4-carvone The acid invention is 3-[N-(2-mercapto-propionyl-amino-acetyl) ]-] Aiming for new therapeutic uses of tetrahydrothiazolyl-4-carvone .
ト記の式(1)。Equation (1) below.
をイfし、MR729としても知られている3−[N−(2−メルカプト−プロ ピオニル−アミノ−アセチル)]−]テトラヒドローチアゾリルー4−カルボン は、欧州特許出願第0079464号に、肝臓保護および気管支分泌活性を有す る化そのため該化合物は抗炎症および免疫刺激剤として有用となった。and 3-[N-(2-mercapto-propylene), also known as MR729. pionyl-amino-acetyl)]-]tetrahydrothiazolyl-4-carvone has hepatoprotective and bronchial secretory activity, according to European Patent Application No. 0079464. The compound has therefore become useful as an anti-inflammatory and immunostimulant.
MR729の薬理学的特性は以下の通りである。The pharmacological properties of MR729 are as follows.
急性毒性 リッヒフィールト(Litchficld)およびウィルコキソン(Wilco xon)の方法、J、 Phart Exp、 Therap、 9[i、 9 9.1949に従って、マウス、ラットおよびラビットについて評価を行った。acute toxicity Litchficld and Wilcoxon xon) method, J, Phart Exp, Therap, 9[i, 9 The evaluation was carried out in mice, rats and rabbits in accordance with 9.1949.
MR729を経口投与および腹腔的投与の両投与を行った。その結果を表1に報 告する。MR729 was administered both orally and intraperitoneally. The results are reported in Table 1. I will inform you.
種族 D L 50 (mg/kg) ラット >4000 1020 デストは、Jcrnc N、 K、、 1lcnry C,、Nordi++ A、^、 (Trnnspl、 Ray、 19.130゜1974)に記載の 方法に従って、C57BII/6マウスに対して実施した。主な抗体反応を、M R729の皮)投与41」後に、羊の赤血球(SRBC)で敏感にしたマウスの 牌臓内の、斑点を形成した細胞の数によって;f価した。対照には、投Ijを行 わなかった3、その結果を表2に報告する。Race D L 50 (mg/kg) Rat >4000 1020 Dest is Jcrnc N, K,, 1lcnry C,, Nordi++ A, ^, (Trnnspl, Ray, 19.130° 1974) The method was performed on C57BII/6 mice. The main antibody reaction is M After administration of R729 skin), mice sensitized with sheep red blood cells (SRBC) The f value was determined by the number of speck-forming cells within the spleen. For control, injection Ij was performed. The results are reported in Table 2.
表2 C57BI/6マウスにおける一rの赤血球(SRBC)に対する1;な抗体反 応への影響。11シ均±S、D、 (n=5)マウス グループ 数 処理 投 与量 牌細胞 1’FC/牌職 対照に対する2 5 MR−72950295 ±33 16637±2713零零 157.83 5 MR−7291002 66±19 10037±4632 55.7PFC・・・5RBCで敏感にさ れたマウスの牌臓内の抗体形成細胞(斑点形成細胞)の数 * P<0.05. **r’<Q、Qlすθp5 ラットの腸分泌物中のIgA濃度に対する影響を、Elson C,0,外(J 、 of l5sunn1.1lcthcxi、 67、101.1984)に 記載の方法を用いて評価した。IgA濃度はELISA法を用いて評価した。M R729は7日間毎日投与した。その結果を表3に報告する。Table 2 Antibody antibodies against single red blood cells (SRBCs) in C57BI/6 mice impact on response. 11 mean ± S, D, (n=5) mouse group number treatment throw Dose tile cell 1'FC/tile cell 2 5 MR-72950295 for control ±33 16637±2713 zero 157.83 5 MR-7291002 66±19 10037±4632 55.7PFC...Sensitive with 5RBC Number of antibody-forming cells (speck-forming cells) in the spleen of mice *P<0.05. **r'<Q, Qlsu θp5 The effect on IgA concentration in rat intestinal secretions was evaluated by Elson C. , of l5sunn1.1lcthcxi, 67, 101.1984) Evaluation was made using the method described. IgA concentration was evaluated using ELISA method. M R729 was administered daily for 7 days. The results are reported in Table 3.
人J マウスの腸分泌物中のI gA濃度に対する影響。平均±S、D、(n=10) 処理 投与量 1gΔ 対照に対する 本対照に対してp<0.01 ヒトの白血球における有量分裂(¥11μg、c、−、r2 )−刺激MR72 9での処理後に植物性血球凝集i(1’llΔ)およびリボポリサツカリド(L PS)によって誘発されるヒト白血球細胞の増殖に対する影響を、Bnyu園A 、IJ、 Cl1n、 Lab、 Invest、 21(97)、 1(19 68)l 、およびI’1irschhorn K、、 rerie Hcmatnlogica、 9.26(1965)+ に記載の方法を用いて 評価した。3H−チミジンをヒト白血球中に入れた。その結果を表4に報告する 。person J Effect on IgA concentration in intestinal secretions of mice. Mean±S, D, (n=10) Treatment Dose 1gΔ vs. control p<0.01 versus main control Mitosis in human leukocytes (¥11 μg, c, -, r2)-stimulated MR72 Phytohemagglutination i (1'llΔ) and ribopolysaccharide (L PS) on the proliferation of human leukocytes induced by Bnyuen A , IJ, Cl1n, Lab, Invest, 21(97), 1(19 68) l, and I'1irschhorn K,, rerie Using the method described in Hcmatnlogica, 9.26 (1965) + evaluated. 3H-thymidine was introduced into human leukocytes. The results are reported in Table 4. .
人凍 植物性血球凝集素(PHA)およびリポポリサツカリド(LPS)により誘発さ れた増殖に関する影響。平均±S、D。Human freezing induced by phytohemagglutinin (PHA) and lipopolysaccharide (LPS) effects on growth. Mean ± S, D.
対照に対してP<0.01 免疫回復テスト アザチオプリンで基準日(Oの日)に処理したマウスについて、牌細胞増殖に対 する有糸分裂の影響を評価するために、試験をFarrant外(J、 III IIunol Metb。P<0.01 vs. control immune recovery test For mice treated with azathioprine on the reference day (day O), the effect on tile cell proliferation was To assess the mitotic effects of IIunol Metb.
ds、 1980)に記載の方法に従って実施した。牌細胞を3日目に得た。結 果を表5に報告する。MR729は0.1日目、2日目に投与した。It was carried out according to the method described in J.D.S., 1980). Plate cells were obtained on the third day. Conclusion The results are reported in Table 5. MR729 was administered on day 0.1 and day 2.
3璋回復テスト 人旦 PWA(2gg/w+1)又はL P S (60gg/ml)誘発増殖に対す る影響。3 Zhang recovery test People's Day against PWA (2gg/w+1) or LPS (60gg/ml)-induced proliferation. influence.
各グループは3匹の動物のプール(poo+)を表す。Each group represents a pool of 3 animals (poo+).
傘対照に対してP<0.01 亜急性抗炎症活性 ラットにおけるカラゲーン膿瘍 テストを、Bcnitz K、 F、外(Arch、 Int、 Pharmc odyn、 144.185.1963年)にして秤量した。その結果を表6に 示す。(平均±S、D、 ; n=9)及9 ラットにおけるカラゲーン肉芽腫 テストを、Boris^、外(Arch、 int、 Pharmccxlyn 、 153.205.1’165年)により記載されたように実施した。薬剤を 411間投与した。5日目に、滲出液を含むのうを取り出した。その結果を表7 に報告する。(平均±S、 E、・n=10)人ヱ 処理 投Ij量 滲出液 対照に対する P上に報告した薬理学的テストは、有 効でありそして人における臨床的有用性を予測する実験モデルとして全体的に認 められる。従って、本発明はまた、免疫刺激および抗炎症活性を有する活性成分 としてMR729を含む薬学的配合物にも関連し、特に、付随する上記の活性の 存在が特別の有益な影響を及ぼす再発性呼吸系感染症の予防用配合物に関する。P<0.01 vs. umbrella control Subacute anti-inflammatory activity Carrageen abscess in rats Test, Bcnitz K, F, External (Arch, Int, Pharmc odyn, 144.185.1963) and weighed. The results are shown in Table 6. show. (Average ± S, D,; n = 9) and 9 Carrageen granuloma in rats Test, Boris^, outside (Arch, int, Pharmccxlyn , 153.205.1'165). drugs It was administered for 411 days. On the fifth day, the sac containing the exudate was removed. Table 7 shows the results. Report to. (Average ± S, E, ・n=10) people Treatment, dosage, exudate, pharmacological tests reported above for control overall recognition as an experimental model to predict clinical utility in humans. I can't stand it. Therefore, the present invention also provides active ingredients with immunostimulatory and anti-inflammatory activity. It also relates to pharmaceutical formulations containing MR729 as It relates to formulations for the prophylaxis of recurrent respiratory infections, the presence of which has a particular beneficial effect.
薬学的配合物の例は例えば、活性成分を100ないし500mg含む錠剤、にお い袋(sachet)、カプセル、小びんである。経口とは異なる投与経路もま た用いることができる。薬量は、患者の体重および状態のようない(つかの要因 に依存するであろうが、通常は1日当たり100mgないし2gの範囲であり、 場合によっていくつかの投与回数に分割してもよい。Examples of pharmaceutical formulations include tablets containing 100 to 500 mg of the active ingredient. These are sachets, capsules, and small bottles. Routes of administration other than oral may also be used. It can also be used. The dosage depends on factors such as the patient's weight and condition. usually ranges from 100 mg to 2 g per day, depending on It may optionally be divided into several doses.
フロントページの続き (51) Int、 C1,6識別記号 ・庁内整理番号C07K 51062 ZNA 8318−4H(81)指定国 EP(AT、BE、CH,DE。Continuation of front page (51) Int, C1,6 identification symbol・Internal office reference number C07K 51062 ZNA 8318-4H (81) Designated country EP (AT, BE, CH, DE.
DK、ES、FR,GB、GR,IE、IT、LU、MC,NL、PT、SE) 、0A(BF、BJ、CF、CG、 CI、 CM、 GA、 GN、 ML、 MR,NE、 SN。DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE) , 0A (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN.
TD、TG)、AT、AU、BB、BG、BR,BY。TD, TG), AT, AU, BB, BG, BR, BY.
CA、CH,CN、CZ、DE、DK、ES、FI、GB、GE、HU、JP、 KG、KP、KR,KZ、LK、LU、LV、MD、MG、MN、MW、NL、 No。CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, No.
NZ、PL、PT、R○、RU、SD、SE、SI、SK、TJ、TT、UA、 US、UZ、VNI A61K 37102 ACDNZ, PL, PT, R○, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VNI A61K 37102 ACD
Claims (1)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT93A000984 | 1993-05-14 | ||
IT93MI000984A IT1264446B1 (en) | 1993-05-14 | 1993-05-14 | ACID 3 (N- (2-MERCAPTO-PROPIONYL-AMINO-ACETYL)) - TETRAHYDROTIAZOLYL-4- CARBOXYL AS AN ANTI-INFLAMMATORY AND IMMUNOSTIMULANT AGENT |
PCT/EP1994/001527 WO1994026272A1 (en) | 1993-05-14 | 1994-05-11 | 3-[n-(2-mercapto-propionyl-amino-acetyl)]-tetrahydro-thiazolyl-4-carboxylic acid as antiinflammatory and immunostimulating agent |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH07509006A true JPH07509006A (en) | 1995-10-05 |
Family
ID=11366162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6524965A Pending JPH07509006A (en) | 1993-05-14 | 1994-05-11 | 3-[N-(2-Mercaptopropionyl-aminoacetyl)]-tetrahydrothiazolyl-4-carboxylic acid as an anti-inflammatory and immunostimulant |
Country Status (4)
Country | Link |
---|---|
JP (1) | JPH07509006A (en) |
AU (1) | AU6969594A (en) |
IT (1) | IT1264446B1 (en) |
WO (1) | WO1994026272A1 (en) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55129265A (en) * | 1979-03-27 | 1980-10-06 | Yoshitomi Pharmaceut Ind Ltd | Interferon-inducing agent |
IT1195287B (en) * | 1981-11-05 | 1988-10-12 | Ausonia Farma Srl | THIAZOLIC DERIVATIVE, PROCEDURE FOR ITS PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS |
IT1202426B (en) * | 1987-01-26 | 1989-02-09 | Poli Ind Chimica Spa | THIAZOLIDIN-4-CARBOXYLIC ACID DERIVATIVE, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT |
IT1216556B (en) * | 1988-04-07 | 1990-03-08 | Poli Ind Chimica Spa | PEPTIDAL DERIVATIVES OF 3_AMINODIIDROTIOFEN_2_ONE, THEIR PREPARATION AND THERAPEUTIC USE. |
IT1241415B (en) * | 1990-03-05 | 1994-01-14 | Yason Srl | ACID DERIVATIVE S- (2-TENOIL) -THYOLACTIC FOR PHARMACOLOGICAL ACTIVITY |
-
1993
- 1993-05-14 IT IT93MI000984A patent/IT1264446B1/en active IP Right Grant
-
1994
- 1994-05-11 AU AU69695/94A patent/AU6969594A/en not_active Abandoned
- 1994-05-11 WO PCT/EP1994/001527 patent/WO1994026272A1/en active Application Filing
- 1994-05-11 JP JP6524965A patent/JPH07509006A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU6969594A (en) | 1994-12-12 |
IT1264446B1 (en) | 1996-09-23 |
ITMI930984A1 (en) | 1994-11-14 |
ITMI930984A0 (en) | 1993-05-14 |
WO1994026272A1 (en) | 1994-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ruskin et al. | Low-dose co-trimoxazole for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus disease | |
Craps et al. | Clinical investigation of agents with prophylactic anti‐allergic effects in bronchial asthma | |
SA92120536B1 (en) | Respiratory form of cyclosporine | |
US4767626A (en) | Remedy for anemia and arthritis | |
Ahumada et al. | Effect of certain adaptogenic plant extracts on drug‐induced narcosis in female and male mice | |
CN1167466C (en) | Oral medicinal preparation | |
WO2016036273A1 (en) | Medicinal agent for preventing and treating respiratory tract diseases | |
US7592327B2 (en) | Asthma/allergy therapy that targets T-lymphocytes and/or eosinophils | |
JPH07509006A (en) | 3-[N-(2-Mercaptopropionyl-aminoacetyl)]-tetrahydrothiazolyl-4-carboxylic acid as an anti-inflammatory and immunostimulant | |
DE2250032C3 (en) | Medicines based on lysine derivatives to combat leukopenia and normalize the percentage composition of the leukocyte picture | |
Yeo et al. | Protective effect of loop diuretics, piretanide and frusemide, against sodium metabisulphite-induced bronchoconstriction in asthma | |
ES2356371T3 (en) | THERAPEUTIC MEDICINES TO INDUCE TOLERANCE. | |
JPS63159324A (en) | Oral vaccine for pollinosis of japanese cedar | |
EP1109557B1 (en) | Use of cetirizine for preventing the onset of asthma | |
US20020058706A1 (en) | Method for treating asthma using pregabalin | |
KR880003973A (en) | Pharmacologically active compounds and uses | |
JPH1045576A (en) | Orally administering agent for rhinitis | |
CN112972462B (en) | Application of panobinostat in preparation of medicine for preventing, relieving and/or treating multiple sclerosis | |
JP2001106630A (en) | Simethicone-containing composition for treatment of ulcerative colitis | |
JPH0967256A (en) | Drug for common cold | |
Samter et al. | On the rationale of treating allergic diseases with bacterial pyrogens | |
Parish et al. | Erythema multiforme due to methaqualone | |
WO2000051580A2 (en) | Asthma/allergy therapy that targets t-lymphocytes and/or eosinophils | |
EA043839B1 (en) | APPLICATION OF GLUTARIMIDE DERIVATIVE TO OVERCOMING RESISTANCE TO STEROIDS AND THERAPY OF DISEASES ASSOCIATED WITH ABERRANT INTERFERON GAMMA SIGNALING | |
JPH0623111B2 (en) | Anti-cataract agent |